BioSig Technologies Gelecekteki Büyüme

Future kriter kontrolleri 2/6

BioSig Technologies kazanç ve gelirinin sırasıyla yıllık 15.6% ve 225.9% oranında artması tahmin edilirken, EPS'nin yıllık 36.8% oranında büyümesi bekleniyor.

Anahtar bilgiler

15.6%

Kazanç büyüme oranı

36.8%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	17.1%
Gelir büyüme oranı	225.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Dec 12

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

Dec 14

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:BSGM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	1	-12	N/A	-8	1
12/31/2024	N/A	-14	N/A	-7	1
9/30/2024	0	-15	-7	-7	N/A
6/30/2024	0	-18	-10	-10	N/A
3/31/2024	0	-25	-13	-13	N/A
12/31/2023	0	-29	-17	-17	N/A
9/30/2023	0	-30	-19	-18	N/A
6/30/2023	0	-32	-20	-20	N/A
3/31/2023	0	-27	-22	-21	N/A
12/31/2022	0	-27	-22	-22	N/A
9/30/2022	0	-29	-24	-23	N/A
6/30/2022	0	-30	-26	-25	N/A
3/31/2022	0	-32	-26	-25	N/A
12/31/2021	0	-32	-27	-26	N/A
9/30/2021	0	-34	-27	-27	N/A
6/30/2021	0	-38	-27	-26	N/A
3/31/2021	0	-49	-28	-28	N/A
12/31/2020	N/A	-52	-27	-27	N/A
9/30/2020	N/A	-57	-25	-24	N/A
6/30/2020	N/A	-51	-22	-22	N/A
3/31/2020	N/A	-40	-18	-18	N/A
12/31/2019	N/A	-34	-16	-15	N/A
9/30/2019	N/A	-25	-15	-15	N/A
6/30/2019	N/A	-23	-13	-13	N/A
3/31/2019	N/A	-21	-12	-11	N/A
12/31/2018	N/A	-18	-11	-10	N/A
9/30/2018	N/A	-17	-10	-10	N/A
6/30/2018	N/A	-15	N/A	-9	N/A
3/31/2018	N/A	-12	N/A	-8	N/A
12/31/2017	N/A	-13	N/A	-7	N/A
9/30/2017	N/A	-10	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-6	N/A
3/31/2017	N/A	-12	N/A	-6	N/A
12/31/2016	N/A	-12	N/A	-5	N/A
9/30/2016	N/A	-12	N/A	-5	N/A
6/30/2016	N/A	-11	N/A	-5	N/A
3/31/2016	N/A	-9	N/A	-4	N/A
12/31/2015	N/A	-10	N/A	-5	N/A
9/30/2015	N/A	-10	N/A	-4	N/A
6/30/2015	N/A	-15	N/A	-4	N/A
3/31/2015	N/A	-11	N/A	-3	N/A
12/31/2014	N/A	-9	N/A	-2	N/A
9/30/2014	N/A	-8	N/A	-2	N/A
6/30/2014	N/A	-6	N/A	-2	N/A
3/31/2014	N/A	-8	N/A	-2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BSGM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: BSGM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: BSGM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: BSGM şirketinin gelirinin (yıllık 225.9% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BSGM şirketinin gelirinin (yıllık 225.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BSGM 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

BioSig Technologies Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 67%, EPS upgraded

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

Consensus revenue estimates decrease by 65%, EPS upgraded

Recent updates

BioSig Technologies, Inc., Annual General Meeting, Dec 31, 2024

BioSig Technologies' Common Stock Deleted from OTC Equity

Nasdaq Hearings Panel Determines to Delist BioSig Technologies' Common Stock

BioSig Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $3.000005 million.

BioSig Technologies, Inc. announced delayed 10-Q filing

BioSig Technologies Regains Compliance with the Minimum Bid Price Requirements in Listing Rule 5550(a)(2)

BioSig Technologies, Inc. Appoints Anthony Amato as Chief Executive Officer

BioSig Technologies, Inc. announced delayed annual 10-K filing

BioSig Technologies Receives Letter from Nasdaq Regarding No Longer Meets the Requirement of Rule 5550(b)(2)

BioSig Technologies Receives a Letter from the Listing Qualifications Department of Nasdaq Stating That the Company Has Not Regained Compliance with the Rule

Biosig Technologies, Inc. Announces Resignation of Kenneth L. Londoner as Chief Executive Officer

BioSig Announces Reduction of its Workforce

Biosig Technologies, Inc. Commences Workforce Reduction Consisted of the Departure of Sixteen Employees

BioSig Technologies, Inc. announced that it expects to receive $1.04 million in funding

BioSig Technologies Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Market Value of Listed Securities

Consensus revenue estimates decrease by 67%, EPS upgraded

Shareholders May Be More Conservative With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation For Now

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

BioSig Technologies, Inc. has filed a Follow-on Equity Offering.

Biosig Technologies, Inc. Appoints Fred Hrkac as Executive Vice President

BioSig Technologies, Inc., Annual General Meeting, Dec 18, 2023

BioSig Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $0.13464 million.

BioSig Technologies, Inc. announced that it has received $0.597497 million in funding

Price target increased by 27% to US$5.63

Consensus revenue estimates decrease by 24%

BioSig Technologies, Inc. announced that it has received $0.549999 million in funding

BioSig Technologies, Inc. Achieves Infrastructure and Technology Progress in Development of Generative AI Platform for Hospitals

Biosig Technologies, Inc. Introduces New Subscription Model for Pure Ep™ Platform, Offering Quicker Access to Latest Features, Customers

Biosig Technologies, Inc.'s Pure Ep Platform Debuts New Automated Features in First Patient Cases

Second quarter 2023 earnings released: US$0.16 loss per share (vs US$0.15 loss in 2Q 2022)

New minor risk - Share price stability

BioSig Technologies, Inc. Advances Collaboration on Machine Learning and Artificial Intelligence Solutions for Healthcare

Price target increased by 8.0% to US$4.50

Consensus EPS estimates fall by 24%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 65%, EPS upgraded

BioSig Technologies, Inc. Announces Chief Financial Officer Changes

BioSig Technologies, Inc. announced that it has received $1.299999 million in funding

BioSig Technologies, Inc. announced that it expects to receive $0.159998 million in funding

BioSig Technologies, Inc. announced that it expects to receive $1.299999 million in funding

BioSig's PURE EP(TM) System Demonstrates Potential Time and Cost Savings At the 15th APHRS Scientific Session in Singapore

Shareholders May Not Be So Generous With BioSig Technologies, Inc.'s (NASDAQ:BSGM) CEO Compensation And Here's Why

BioSig Technologies Receives a Letter from the Nasdaq Stock Market

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$4.17

BioSig Technologies, Inc., Annual General Meeting, Dec 20, 2022

BioSig Technologies Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price

BioSig in acquisition pact with San Antonio Hospital for cardiac signal system

BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

BioSig: No Changes To Hold Thesis Following Q2 Earnings

Consensus forecasts updated

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSig Technologies Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 55%

BioSig signs purchase deal with Kansas City's Overland Park Regional hospital

BioSig: PURE EP Economics Trade Exhausted

BioSig Technologies, Inc.’s PURE EP™ System to be Featured During EPLive 2022

Consensus revenue estimates fall by 18%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin